Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AGS16F |
Synonyms | |
Therapy Description |
AGS16F is a monoclonal antibody against ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) linked to the cytotoxic drug monomethyl auristatin F (MMAF), which may result in apoptosis of ENPP3-expressing tumor cells and decreased tumor growth (PMID: 26589436). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGS16F | AGS16C3F|AGS16M8F|AGS-16C3F|AGS-16M8F | AGS16F is a monoclonal antibody against ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) linked to the cytotoxic drug monomethyl auristatin F (MMAF), which may result in apoptosis of ENPP3-expressing tumor cells and decreased tumor growth (PMID: 26589436). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | renal cell carcinoma | not applicable | AGS16F | Phase I | Actionable | In a Phase I trial, treatment with AGS16F (AGS-16CSF) at the recommended phase 2 dose demonstrated safety and resulted in a partial response in 23% (3/13) of patients with metastatic renal cell carcinoma including 2 patients with clear cell and 1 patient with papillary histology, and a disease control rate of 92% (12/13) (PMID: 29848572). | 29848572 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02639182 | Phase II | AGS16F Axitinib | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | CAN | 0 |